At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 389 enrolled
Drug / intervention
conjugated polysaccharide menC vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life.
Centro Superior de Investigación en Salud Publica·interventional·Posted Oct 26, 2006·Updated Oct 11, 2013
In Brief
A Phase 4 clinical trial evaluating conjugated polysaccharide menC vaccine for Meningococcal Infection. Completed, enrolled 389 participants across 2 sites.
Detailed Summary
The purpose of the study is to evaluate the immune response of toddlers, to a booster dose in the second year of life of two meningococcal C conjugated polysaccharide vaccine, and to assess the interchangeability of the two different vaccines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Infection
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartJan 2007
Primary CompletionMay 2008
Study CompletionMay 2009
TodayJul 2026
First PostedOct 26, 2006
Enrollment StartJan 1, 2007
Primary CompletionMay 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.7 years ago
Interventions
conjugated polysaccharide menC vaccinebiological
Booster vaccine dose at 14 to 18 months.